Quarterly ResultMay 5, 2026, 09:17 AM
Neuronetics Faces Going Concern Doubt; Q1 Revenue Up 7.7%
AI Summary
Neuronetics, Inc. reported a substantial doubt about its ability to continue as a going concern, primarily due to a projected failure to meet its March 31, 2027 minimum revenue covenant, which could lead to its lender calling the credit facility. Despite this, the company's Q1 2026 financial results showed an increase in total revenue by 7.7% to $34.45 million and a narrowed net loss to $(10.78) million. Cash and cash equivalents, however, significantly decreased to $13.21 million from $28.13 million at the end of 2025.
Key Highlights
- Neuronetics faces substantial doubt about its ability to continue as a going concern due to projected failure to meet its March 31, 2027 revenue covenant.
- Total revenue for Q1 2026 increased 7.7% to $34.45 million from $31.98 million in Q1 2025.
- Net loss for Q1 2026 narrowed to $(10.78) million, an improvement from $(12.69) million in Q1 2025.
- Basic and diluted net loss per share improved to $(0.16) in Q1 2026 from $(0.21) in Q1 2025.
- Cash and cash equivalents decreased to $13.21 million as of March 31, 2026, from $28.13 million at December 31, 2025.
- Net cash used in operating activities improved to $(9.42) million in Q1 2026 from $(16.99) million in Q1 2025.
- U.S. clinic revenue increased to $21.53 million in Q1 2026, representing 63% of total U.S. revenues.
- Long-term debt, net, stood at $61.30 million as of March 31, 2026, with $65.0 million outstanding under its credit facility.